FDA Grants Genentech's Obinutuzumab Priority Review for Previously Untreated CLL
July 03, 2013 at 05:56 AM EDT
Genentech, a member of the Roche Group OTC: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for … Genentech,
